NEW Episode 105 · Season 26 Oct 15, 2026 · 25 min
Chronic Lymphocytic Leukemia — Microlearning Activity 1
Featuring perspectives from Dr Catherine C Coombs, including the following topics: Early versus delayed addition of obinutuzumab to acalabrutinib and venetoclax in treatment-naïve chronic lymphocytic leukemia (CLL) (0:00) Feasibility of discontinuation of Bruton tyrosine kinase (BTK) inhibitor therapy in CLL; minimal residual disease and disease monitoring (4:10) Ongoing Phase III trials of BTK inhibitor/B-cell lymphoma 2 inhibitor combinations in previously untreated CLL (10:05) Pirtobrutinib as first-line therapy for CLL and long-term safety data (15:22) CME information and select publications
Listener moments on the timeline Moments: 0
0:00 Early versus delayed addition of obinutuzumab to acalabrutinib and venetoclax in treatment-naïve chronic lymphocytic leu 24:32